Bausch Health Companies Inc. Forecasted to Post Q2 2024 Earnings of $1.17 Per Share (TSE:BHC)

Bausch Health Companies Inc. (TSE:BHCFree Report) – Equities researchers at Zacks Research lowered their Q2 2024 EPS estimates for Bausch Health Companies in a report issued on Thursday, May 23rd. Zacks Research analyst R. Department now forecasts that the company will earn $1.17 per share for the quarter, down from their prior estimate of $1.27. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2024 earnings at $1.40 EPS, FY2024 earnings at $4.88 EPS, Q1 2025 earnings at $1.13 EPS and Q4 2025 earnings at $1.79 EPS.

Bausch Health Companies (TSE:BHCGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported C$0.80 EPS for the quarter, missing the consensus estimate of C$1.02 by C($0.22). The business had revenue of C$2.90 billion during the quarter, compared to analyst estimates of C$2.98 billion. Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 5.07%.

Separately, Royal Bank of Canada increased their target price on shares of Bausch Health Companies from C$8.00 to C$9.00 and gave the stock a “sector perform” rating in a research report on Friday, February 23rd.

View Our Latest Research Report on BHC

Bausch Health Companies Trading Down 2.3 %

TSE:BHC opened at C$8.51 on Monday. The stock has a market cap of C$3.12 billion, a PE ratio of -5.04, a price-to-earnings-growth ratio of 0.21 and a beta of 0.90. Bausch Health Companies has a fifty-two week low of C$8.45 and a fifty-two week high of C$15.43. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.23 and a quick ratio of 0.58. The stock’s 50-day moving average is C$11.66 and its two-hundred day moving average is C$11.10.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Recommended Stories

Earnings History and Estimates for Bausch Health Companies (TSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with's FREE daily email newsletter.